RxDoctor Payments Data

Craig Feaster, MD

Child & Adolescent Psychiatry · State College, PANPI 1912905795

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,980 of the $18,288 with a category attached, or 60.0%. Corium, LLC accounts for 77.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $10,567 and has fallen 86.2% since, to $1,455 in 2025. Among child & adolescent psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,288in general payments, 2019–2025

Across 258 payments — averaging $70.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corium, LLC$14K
  • Supernus Pharmaceuticals, Inc.$743
  • Otsuka America Pharmaceutical, Inc.$642
  • Johnson & Johnson$501
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$491
  • Alkermes, Inc.$399
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$2,44013%
  • Speaking & faculty fees$10,98060%
  • Travel & lodging$1901%
  • Food & beverage$4,67726%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,288 in reported general payments places this provider in the 95th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

See all child & adolescent psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,863
Medicare patients
22
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole20$55,843
VraylarCariprazine Hcl16$24,845
QelbreeViloxazine Hcl14$8,565
AzstarysSerdexmethylphen/Dexmethylphen19$7,613
TrintellixVortioxetine Hydrobromide17$7,594
IntunivGuanfacine Hcl13$3,824
Haloperidol101$2,961
Atomoxetine Hcl45$2,793
Guanfacine Hcl95$2,674
Aripiprazole84$1,731
Lamotrigine157$1,368
Clomipramine Hcl17$1,332
Prazosin Hcl66$994
Oxcarbazepine17$977
Bupropion XlBupropion Hcl31$959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$642$55,84320 claims
AbbVieVraylar$221$24,84516 claims
Supernus Pharmaceuticals, Inc.Qelbree$743$8,56514 claims
Corium, LLCAzstarys$14,193$7,61319 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$33$7,59417 claims
Shire North American Group IncIntuniv$38$3,82413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

Other child & adolescent psychiatry in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →